trending Market Intelligence /marketintelligence/en/news-insights/trending/7g08ln3p7q0cy12ufm-itw2 content esgSubNav
In This List

Blueprint Medicines enters collaboration, license agreement in China

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Blueprint Medicines enters collaboration, license agreement in China

Blueprint Medicines Corp. entered an exclusive collaboration and license agreement with CStone Pharmaceuticals Co. Ltd., a privately held drug developer in China.

The Cambridge, Mass.-based biopharmaceutical company granted CStone the rights to develop and commercialize its cancer drugs avapritinib, BLU-554 and BLU-667 in Greater China. Blueprint Medicines retains the rights to the products in the rest of the world.

CStone agreed to pay $40 million up front for the rights. Additionally, Blueprint Medicines can receive about $346 million in potential milestone payments, along with tiered sales royalties on licensed products.

Blueprint Medicines CEO Jeff Albers said the agreement can expand its ability to address patient needs in Greater China, as well as support the global development of its drugs.

The company is developing avapritinib to treat gastrointestinal stromal tumors and systemic mastocytosis. BLU-554 is meant to treat hepatocellular carcinoma, the most common type of primary liver cancer. BLU-667 is being developed to treat certain solid tumors, including lung and thyroid cancers.